Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company applies science and its global resources to improve health and well-being at every stage of life. Pfizer's diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many consumer health care products. The Company operates in two business segments: Biopharmaceutical and Diversified. Biopharmaceutical includes the Primary Care, Specialty Care, Established Products, Emerging Markets and Oncology customer-focused units. Diversified includes Animal Health products that prevent and treat diseases in livestock and companion animals, and Consumer Healthcare products.

Pfizer develops and produces medicines and vaccines for a wide range of conditions including in the areas of immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. Pfizer's products include Lipitor (atorvastatin, used to lower LDL blood cholesterol); Lyrica (pregabalin, for neuropathic pain/fibromyalgia); Diflucan (fluconazole, an oral antifungal medication); Zithromax (azithromycin, an antibiotic); Viagra (sildenafil, for erectile dysfunction); and Celebrex/Celebra (celecoxib, an anti-inflammatory drug).

Company Growth (employees)
New York, US
Size (employees)
96,500 (est)-1%
Pfizer was founded in 1848 and is headquartered in New York, US

Key People at Pfizer

Ian C. Read

Ian C. Read

Chairman & CEO
Frank A. D'Amelio

Frank A. D'Amelio

EVP, CFO & Business Operations
Laurie J. Olson

Laurie J. Olson

EVP of Strategy, Portfolio and Commercial Operations
Chuck Hill

Chuck Hill

Executive Vice President, Worldwide Human Resources
Rady Johnson

Rady Johnson

Executive VP, Chief Compliance And Risk Officer
Mikael Dolsten

Mikael Dolsten

President, Worldwide Research & Development
Doug Lankler

Doug Lankler

Executive VP, General Counsel
Freda C. Lewis-Hall

Freda C. Lewis-Hall

EVP & Chief Medical Officer

Pfizer Office Locations

Pfizer has offices in New York, Buenos Aires, Bentley, Shanghai and in 40 other locations
New York, US (HQ)
235 East 42nd Street

Pfizer Metrics

Pfizer Financial Metrics

Revenue (2016)

$52.8 b

Revenue growth (2015-16), %


Gross profit

$40.5 b

Gross profit margin (2016), %


Net income (2016)

$7.2 b

Market capitalization (21-Mar-2017)

$204.8 b

Closing share price (21-Mar-2017)

Pfizer's current market capitalization is $204.8 b.
Pfizer's revenue was reported to be $52.8 b in FY, 2016 which is a 8.1% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$51.6 b$49.6 b$48.9 b$52.8 b

Revenue growth, %


Cost of goods sold

$9.6 b$9.6 b$9.6 b$12.3 b

Gross profit

$42 b$40 b$39.2 b$40.5 b

Gross profit Margin, %


Sales and marketing expense

$14.4 b$14.1 b$14.8 b$14.8 b

R&D expense

$6.7 b$8.4 b$7.7 b$7.9 b

Operating expense total

$21 b$22.5 b$22.5 b$22.7 b


$11.4 b$9.1 b$7 b$7.2 b

EBIT margin, %


Pre tax profit

$15.7 b$12.2 b$9 b$8.4 b

Income tax expense

$4.3 b$3.1 b$2 b$1.1 b

Net Income

$22.1 b$9.2 b$7 b$7.2 b
Y, 2011Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016


$3.2 b$10.1 b$2.2 b$3.3 b$3.6 b


$6.2 b$5.7 b

Current Assets

$56.2 b$57.7 b$43.8 b$38.9 b


$12.4 b$11.8 b


$42.5 b$42.1 b$48.2 b$54.4 b

Total Assets

$172.1 b$169.3 b$167.5 b$171.6 b

Accounts Payable

$3.2 b$3.4 b$3.6 b$4.5 b

Dividends Payable

$1.7 b$1.7 b$1.9 b$1.9 b

Total Debt

$30.5 b$31.5 b$28.8 b

Current Liabilities

$23.4 b$21.6 b$29.4 b$31.1 b

Common Stock

$461 m

Preferred Stock

$24 m

Additional Paid-in Capital

$77.3 b$79 b$81 b$82.7 b

Retained Earnings

$69.7 b$72.2 b$72 b$71.8 b

Total Equity

$76.6 b$71.6 b

Debt to Equity Ratio

0.4 x0.4 x

Debt to Assets Ratio

0.2 x0.2 x0.2 x

Financial Leverage

2.2 x2.4 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$22.1 b$9.2 b

Accounts Receivable

$940 m$148 m$21 m($134 m)


($538 m)$175 m($199 m)$365 m

Accounts Payable

$382 m$297 m$254 m$871 m

Cash From Operating Activities

$17.8 b$16.9 b$14.5 b$15.9 b

Purchases of PP&E

($1.2 b)($1.2 b)($1.4 b)($1.8 b)

Cash From Investing Activities

($10.6 b)($5.7 b)($3 b)($7.8 b)

Short-term Borrowings

($1.2 b)($8.2 b)

Long-term Borrowings

($4.1 b)($2.1 b)($3 b)($7.7 b)

Dividends Paid

($6.6 b)($6.6 b)($6.9 b)($7.3 b)

Interest Paid

$1.7 b$1.6 b$1.3 b$1.5 b

Income Taxes Paid

$2.9 b$2.1 b$2.4 b$2.5 b

Pfizer Operating Metrics

Y, 2014Y, 2015Y, 2016

Discovery Projects


Active Clinical Studies


Ongoing Phase III Programs


Drugs Approved by FDA


Pfizer Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
MedivationAugust 22, 2016$14 b
AllerganNovember 23, 2015$160 b

Pfizer Market Value History

Pfizer Revenue Breakdown

Pfizer Median Salaries

Source: 241 public H-1B filings from Pfizer

Pfizer Online Presence

Pfizer News

Pfizer Company Life

You may also be interested in